Related references
Note: Only part of the references are listed.Brexpiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations
Ahmed Elmokadem et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment
Christopher D. Bruno et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study
Akitoyo Hishimoto et al.
ADVANCES IN THERAPY (2022)
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies
Martin A. Katzman et al.
JOURNAL OF AFFECTIVE DISORDERS (2022)
Visualizing classification of drugs used in psychotic disorders: A 'subway map' representing mechanisms, established classes and informal categories
Crystal Zhou et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2022)
Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-term Studies
Christoph U. Correll et al.
JOURNAL OF CLINICAL PSYCHIATRY (2022)
An open-label, positron emission tomography study of the striatal D2/D3 receptor occupancy and pharmacokinetics of single-dose oral brexpiprazole in healthy participants
Dean F. Wong et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Safety of switching to brexpiprazole in Japanese patients with schizophrenia: A post-hoc analysis of a long-term open-label study
Jun Ishigooka et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2021)
Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania
Eduard Vieta et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in special populations
Adam Wichniak et al.
PSYCHIATRIA POLSKA (2021)
The position statement of the Working Group of the Polish Psychiatric Association on the use of D2/D3 dopamine receptor partial agonists in the treatment of mental disorders
Adam Wichniak et al.
PSYCHIATRIA POLSKA (2021)
In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole
Hiroyuki Sasabe et al.
XENOBIOTICA (2021)
Investigation of the impact of grapefruit juice, pomegranate juice and tomato juice on pharmacokinetics of brexpiprazole in rats using UHPLC-QTOF-MS
Disha Thakkar et al.
BIOMEDICAL CHROMATOGRAPHY (2021)
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium
Gustavo H. Vazquez et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2021)
Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials
Michel Sabe et al.
NPJ SCHIZOPHRENIA (2021)
20-Apr-2021 Effect of Switching to Brexpiprazole on Plasma Homovanillic Acid Levels and Antipsychotic-Related Side Effects in Patients with Schizophrenia or Schizoaffective Disorder
Mizue Ichinose et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
Tetsuro Kikuchi et al.
NEUROPSYCHOPHARMACOLOGY REPORTS (2021)
Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval
Hiroaki Okayasu et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Association between previous high-dose antipsychotic therapy and brexpiprazole discontinuation after the initiation of brexpiprazole in patients with schizophrenia or schizoaffective disorder
Yusaku Yoshimura et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2020)
Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
Stephen R. Marder et al.
ACTA NEUROPSYCHIATRICA (2020)
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis
Barbara B. Barton et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials
Ayman Reyad et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2020)
Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis
Taro Kishi et al.
PSYCHOPHARMACOLOGY (2020)
Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms:Post-hocanalysis of short- and long-term studies
Nicole Meade et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2020)
Effect of brexpiprazole on control of impulsivity in schizophrenia: A randomized functional magnetic resonance imaging study
Theo G. M. van Erp et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2020)
Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie
Georgios Schoretsanitis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Effect of Brexpiprazole on Prolactin and Sexual Functioning An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
Anita H. Clayton et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Long-Term Efficacy and Safety of Brexpiprazole in Elderly Japanese Patients with Schizophrenia: A Subgroup Analysis of an Open-Label Study
Ken Inada et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2020)
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder
Michael Bauer et al.
ACTA NEUROPSYCHIATRICA (2019)
A pilot study of brexpiprazole for bipolar depression
E. Sherwood Brown et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone
Filippo Corponi et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2019)
Effect of Brexpiprazole on Prolactin An Analysis of Short- and Long-Term Studies in Schizophrenia
Jelena Ivkovic et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
Christoph U. Correll et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2019)
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Mary Hobart et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
Effect of Brexpiprazole on Agitation and Hostility in Patients With Schizophrenia Post Hoc Analysis of Short- and Long-Term Studies
Leslie Citrome et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2019)
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies
Michael E. Thase et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2019)
Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia
Blazej Misiak et al.
PSYCHIATRIA POLSKA (2018)
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Massimo Carlo Mauri et al.
CLINICAL PHARMACOKINETICS (2018)
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
Mary Hobart et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
Andy Forbes et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2018)
Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies
J. Craig Nelson et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study
Jun Ishigooka et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
Jun Ishigooka et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study
Ulla Lepola et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2018)
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder
Mary Hobart et al.
JOURNAL OF CLINICAL PSYCHIATRY (2018)
The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder
Awais Aftab et al.
EXPERT OPINION ON DRUG DISCOVERY (2017)
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Leslie Citrome
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole
Joshua S. Frankel et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2017)
Mechanism of action of cariprazine
Stephen M. Stahl
CNS SPECTRUMS (2016)
The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study
Leslie Citrome et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2016)
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study
Maurizio Fava et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Overview of short- and long-termtolerability and safety of brexpiprazole in patients with schizophrenia
John M. Kane et al.
SCHIZOPHRENIA RESEARCH (2016)
Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies
Christoph U. Correll et al.
SCHIZOPHRENIA RESEARCH (2016)
Schizophrenia relapse, patient considerations, and potential role of lurasidone
Leslie Citrome
Patient Preference and Adherence (2016)
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
Lori L. Davis et al.
BRAIN AND BEHAVIOR (2016)
Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
Christoph U. Correll et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2015)
Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
Michael E. Thase et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Brexpiprazole I: In Vitro and In Vivo Characterization of a Novel Serotonin-Dopamine Activity Modulator
Kenji Maeda et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization
Chris A. Oosterhof et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S. Miyamoto et al.
MOLECULAR PSYCHIATRY (2012)
Share Paper
